Pulse Biosciences (PLSE) Total Current Liabilities (2015 - 2025)

Pulse Biosciences' Total Current Liabilities history runs 11 years deep, the most recent figure standing at $7.9 million for Q4 2025.

• On a quarterly basis, Total Current Liabilities fell 21.2% year-over-year to $7.9 million in Q4 2025; TTM through Dec 2025 was $7.9 million, a 21.2% decrease from a year earlier, with the FY2025 full-year figure at $7.9 million, down 21.2% from the prior year.
• Total Current Liabilities retreated to $7.9 million in Q4 2025 per PLSE's latest filing, from $9.7 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $10.1 million in Q4 2024 and bottomed at $5.1 million in Q1 2024.
• The 5-year median for Total Current Liabilities is $7.3 million (2022), against an average of $7.5 million.
• Across the five-year window, Total Current Liabilities soared 152.08% in 2021 and dropped 27.32% in 2024, its largest moves.
• Year by year, Total Current Liabilities stood at $6.7 million in 2021, then retreated by 10.84% to $6.0 million in 2022, then climbed by 12.16% to $6.7 million in 2023, then soared by 49.9% to $10.1 million in 2024, then declined by 21.2% to $7.9 million in 2025.
• Per Business Quant, the three latest PLSE Total Current Liabilities figures stand at $7.9 million (Q4 2025), $9.7 million (Q3 2025), and $9.0 million (Q2 2025).